var data={"title":"Hypertriglyceridemia-induced acute pancreatitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hypertriglyceridemia-induced acute pancreatitis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/contributors\" class=\"contributor contributor_credentials\">Andres Gelrud, MD, MMSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/contributors\" class=\"contributor contributor_credentials\">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/contributors\" class=\"contributor contributor_credentials\">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 01, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia (HTG) is among the most common cause of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Early clinical recognition of HTG-induced pancreatitis (HTGP) is important to provide appropriate therapy and to prevent further episodes [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1,2,4-6\" class=\"abstract_t\">1,2,4-6</a>]. This topic will review the etiology, clinical features, and management of acute HTGP. Long-term therapy of HTG with diet restriction and lipid-lowering medications is discussed separately. (See <a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;</a> and <a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">&quot;Lipid lowering with diet or dietary supplements&quot;</a> and <a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">&quot;Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3440399298\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia (HTG) is defined by fasting serum triglyceride level of &gt;150 <span class=\"nowrap\">mg/dL</span> (1.7 <span class=\"nowrap\">mmol/L)</span>. HTG is classified based on the degree of elevation as follows [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild (150 to 199 <span class=\"nowrap\">mg/dL</span> 1.7 to 2.2 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate (200 to 999 <span class=\"nowrap\">mg/dL,</span> 2.3 to 11.2 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe HTG (1000 to 1999 <span class=\"nowrap\">mg/dL,</span> 11.3 to 22.5 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Very severe HTG (&ge;2000 <span class=\"nowrap\">mg/dL,</span> &gt;22.6 <span class=\"nowrap\">mmol/L)</span> </p><p/><p>HTG is considered a significant risk for acute pancreatitis when levels are &gt;1000 <span class=\"nowrap\">mg/dL</span> (11.3 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/6\" class=\"abstract_t\">6</a>]. </p><p class=\"headingAnchor\" id=\"H2247604236\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3186240998\"><span class=\"h2\">Prevalence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia-induced pancreatitis (HTGP) cause 1 to 14 percent of all cases of acute pancreatitis and up to 56 percent of pancreatitis cases during pregnancy [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1,3-5\" class=\"abstract_t\">1,3-5</a>]. There are demographic differences between patients with HTGP and other causes of pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/7,8\" class=\"abstract_t\">7,8</a>]. As an example, in a prospective study of 400 consecutive cases of acute pancreatitis, patients with HTGP were younger in age (44 versus 52 years), predominantly male (65 versus 45 percent), obese (57 percent versus 34 percent), and diabetic (38 versus 17 percent) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/8\" class=\"abstract_t\">8</a>]. </p><p class=\"headingAnchor\" id=\"H806594555\"><span class=\"h2\">Risk of acute pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mild hypertriglyceridemia is associated with a low risk of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/2,9-11\" class=\"abstract_t\">2,9-11</a>]. The risk increases progressively with serum triglyceride levels over 500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> with the risk increasing markedly with levels over 1000 <span class=\"nowrap\">mg/dL</span> (11.3 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/10,12,13\" class=\"abstract_t\">10,12,13</a>]. The risk of developing acute pancreatitis is approximately 5 percent with serum triglycerides &gt;1000 <span class=\"nowrap\">mg/dL</span> (11.3 <span class=\"nowrap\">mmol/L)</span> and 10 to 20 percent with triglycerides &gt;2000 <span class=\"nowrap\">mg/dL</span> (22.6 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/14\" class=\"abstract_t\">14</a>]. </p><p class=\"headingAnchor\" id=\"H3785591660\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both primary (genetic) and secondary disorders of lipoprotein metabolism are associated with hypertriglyceridemia-induced pancreatitis (HTGP). </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Primary hypertriglyceridemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Types I (high chylomicrons), IV (high very low density lipoprotein [VLDL]), and V (high chylomicrons and VLDL) dyslipidemias are associated with severe hypertriglyceridemia (HTG) and an increased risk of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/15\" class=\"abstract_t\">15</a>]. </p><p>Type I dyslipidemia, also known as familial chylomicronemia, often presents in infancy and is caused by an autosomal recessive trait of lipoprotein lipase deficiency. Patients with type I dyslipidemia can present with acute pancreatitis in the absence of an exacerbating condition. In contrast, patients with type IV and V dyslipidemia do not have sufficiently elevated serum triglyceride levels to cause acute pancreatitis in the absence of contributing environmental or hormonal factors. (See <a href=\"#H4\" class=\"local\">'Secondary hypertriglyceridemia'</a> below.)</p><p>Type IV dyslipidemia also known as familial HTG or familial combined hyperlipidemia, is a complex genetic disorder in which the interaction of multiple susceptibility genes with environmental components contribute to the phenotype. The pathogenic genetic variants predisposing to HTG do not correlate perfectly with the phenotype, and new genes and variants continue to be recognized [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Patients usually present with acute pancreatitis in adulthood. </p><p>Type V dyslipidemia, known as primary mixed HTG, is similar to Type I with a high risk of acute pancreatitis. However, it is a complex genetic disorder with a higher prevalence, and generally presents in adulthood. Inherited disorders of lipid metabolism are discussed in detail separately. (See <a href=\"topic.htm?path=familial-hypercholesterolemia-in-adults-overview\" class=\"medical medical_review\">&quot;Familial hypercholesterolemia in adults: Overview&quot;</a> and <a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia\" class=\"medical medical_review\">&quot;Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Secondary hypertriglyceridemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Various conditions can raise triglycerides and lead to HTGP.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diabetes mellitus</strong> &ndash; Poorly controlled diabetes mellitus (types 1 and 2) and diabetic ketoacidosis can trigger HTGP [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1,18-20\" class=\"abstract_t\">1,18-20</a>]. Pancreatitis in diabetic ketoacidosis (DKA) usually occurs with severe metabolic acidosis characterized by a low serum pH (&lt;7.1) and high anion gap [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/20\" class=\"abstract_t\">20</a>]. Marked elevation of serum triglycerides occur during episodes of DKA. Lack of insulin results in lipolysis in adipose tissue with release of free fatty acids. Increased delivery of free fatty acids to the liver leads to high output of very low density lipoproteins, which coupled with the inhibition of lipoprotein lipase in peripheral tissues, results in hypertriglyceridemia. (See <a href=\"#H10\" class=\"local\">'Insulin'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Medications</strong> &ndash; Hormone supplementation with estrogen and selective estrogen receptor modulator, <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, can raise serum triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/21,22\" class=\"abstract_t\">21,22</a>]. Other medications associated with elevated serum triglyceride levels include <a href=\"topic.htm?path=clomiphene-drug-information\" class=\"drug drug_general\">clomiphene</a>, protease inhibitors, antiretroviral agents, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, <a href=\"topic.htm?path=mirtazapine-drug-information\" class=\"drug drug_general\">mirtazapine</a>, retinoids, thiazide diuretics, and beta-blockers. (See <a href=\"topic.htm?path=hypertriglyceridemia#H8\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;, section on 'Causes'</a> and <a href=\"topic.htm?path=etiology-of-acute-pancreatitis\" class=\"medical medical_review\">&quot;Etiology of acute pancreatitis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pregnancy</strong> &ndash; Although pregnancy causes an increase in serum triglycerides that peaks in the third trimester, the total serum triglyceride level rarely exceeds 300 <span class=\"nowrap\">mg/dL</span> (3.3 <span class=\"nowrap\">mmol/L),</span> a concentration that is not sufficient to cause acute pancreatitis. Cases of nongenetic, nonfamilial pregnancy-induced HTG have been reported but are rare [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/23\" class=\"abstract_t\">23</a>]. Most cases of HTGP that occurs during pregnancy are attributable to underlying familial HTG. &#160;(See <a href=\"topic.htm?path=etiology-of-acute-pancreatitis#H19\" class=\"medical medical_review\">&quot;Etiology of acute pancreatitis&quot;, section on 'Pregnancy'</a> and <a href=\"topic.htm?path=familial-hypercholesterolemia-in-adults-overview\" class=\"medical medical_review\">&quot;Familial hypercholesterolemia in adults: Overview&quot;</a> and <a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia\" class=\"medical medical_review\">&quot;Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Alcohol</strong> &ndash; It is unclear whether alcohol directly causes HTGP or exacerbates an underlying genetic hyperlipidemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/2\" class=\"abstract_t\">2</a>]. Alcohol increases serum triglyceride concentrations in a dose-dependent manner. In a study of approximately 8000 men and women, the prevalence of serum triglyceride concentrations above 227 <span class=\"nowrap\">mg/dL</span> (2.5 <span class=\"nowrap\">mmol/L)</span> increased from 8 to 20 percent with an increase in alcohol intake from three to nine or more drinks per day [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/24\" class=\"abstract_t\">24</a>]. In most cases, the triglyceride elevations with alcohol intake are transient and likely to be an epiphenomenon rather than a cause of pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=etiology-of-acute-pancreatitis#H8\" class=\"medical medical_review\">&quot;Etiology of acute pancreatitis&quot;, section on 'Alcohol'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypothyroidism</strong> &ndash; Hypothyroidism is associated with hypertriglyceridemia, which in rare cases can be severe enough to result in HTGP [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/26,27\" class=\"abstract_t\">26,27</a>].</p><p/><p class=\"headingAnchor\" id=\"H1937641612\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Triglycerides themselves do not appear to be toxic. Rather, it is the breakdown of triglycerides into toxic free fatty acids (FFA) by pancreatic lipases that are the cause of lipotoxicity during acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/28,29\" class=\"abstract_t\">28,29</a>]. The severity of acute pancreatitis in patients with hypertriglyceridemia (HTG) is dependent on both the inflammatory response caused by pancreatitis itself, plus the injury caused by lipotoxicity from triglyceride hydrolysis. </p><p>In most cases, the HTG is transient and returns to near normal within two to three days, depending on etiology [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/30\" class=\"abstract_t\">30</a>]. However, severe or very severe HTG plus high lipase levels (&gt;3 times the upper limit of normal) are associated with very high FFA levels and can further be complicated by systemic inflammation from both acute pancreatitis, direct activation of toll-like receptor (TLR) 2 and TLR4 by FFA and direct lipotoxicity [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/28,31\" class=\"abstract_t\">28,31</a>]. There are no clear biomarkers to determine the effects of lipotoxicity independent of acute pancreatitis with normal triglyceride levels, but several studies have noted a drop in serum calcium levels in more severe cases [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/31,32\" class=\"abstract_t\">31,32</a>]. (See <a href=\"#H3440399298\" class=\"local\">'Terminology'</a> above.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H2925826169\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial presentation of hypertriglyceridemia-induced pancreatitis (HTGP) is similar to that of acute pancreatitis due to other causes with persistent severe epigastric abdominal pain, nausea, and vomiting. Most adults with HTGP present with symptoms in the fifth decade of life. However, patients with some inherited disorders of HTG (eg, Type I hyperlipidemia) can develop attacks of acute pancreatitis in early childhood or adolescence. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-pancreatitis#H2\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of acute pancreatitis&quot;, section on 'Clinical features'</a> and <a href=\"#H3\" class=\"local\">'Primary hypertriglyceridemia'</a> above.)</p><p>Physical examination findings suggestive of underlying hypertriglyceridemia (HTG) may be present in patients with HTGP. These include eruptive xanthomas over the extensor surfaces of the arms, legs, buttocks, and back due to persistent hyperchylomicronemia and hepatosplenomegaly from fatty infiltration [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/33-35\" class=\"abstract_t\">33-35</a>]. Lipemia retinalis may be seen in patients with triglyceride concentrations exceeding 4000 <span class=\"nowrap\">mg/dL</span> (45 <span class=\"nowrap\">mmol/L)</span>. In this condition, the retinal arterioles and venules, and often the fundus itself, develop a pale pink color due to light scattering by large chylomicrons. Vision is not affected and lipemia retinalis is reversible with reduction of triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/33,35\" class=\"abstract_t\">33,35</a>].</p><p>Patients with HTGP tend to have severe pancreatitis as compared with patients with other causes of pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/5,7,13,31,36\" class=\"abstract_t\">5,7,13,31,36</a>]. In a cohort study of 400 consecutive patients with acute pancreatitis, of whom 210 has triglycerides measured within 72 hours of presentation, 86 had hypertriglyceridemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/8\" class=\"abstract_t\">8</a>]. Patients with hypertriglyceridemia were more likely to have persistent organ failure as compared with patients with normal triglycerides (40 percent versus 17 percent).</p><p>The degree of triglyceride elevation is associated with the severity of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/5,7,8,13\" class=\"abstract_t\">5,7,8,13</a>]. However, other factors such as the pancreatic lipase activity, the efficiency of clearing FFA from the serum, and the severity of the underlying pancreatic injury are also likely to influence the severity of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/7,13,37\" class=\"abstract_t\">7,13,37</a>]. In a retrospective study of 1539 patients with acute pancreatitis in which 461 (30 percent) had elevated triglyceride levels, the rates of severe acute pancreatitis increased with increasing triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/7\" class=\"abstract_t\">7</a>]. Among 112 patients with severe or very severe HTG, acute necrotic fluid collections and pancreatic necrosis developed in 32 (29 percent) and 39 (35 percent), respectively [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/7\" class=\"abstract_t\">7</a>]. Furthermore, the proportion of patients with persistent organ failure, multiple organ failure, and persistent SIRS increased with the degree of HTG.</p><p class=\"headingAnchor\" id=\"H3539763974\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At high triglyceride levels, the serum becomes lactescent (milky coloration) (<a href=\"image.htm?imageKey=GAST%2F58261\" class=\"graphic graphic_picture graphicRef58261 \">picture 1</a>). Elevated triglyceride levels can alter routine measurements of sodium, amylase, and low density lipoprotein. The excess triglyceride in a serum sample can displace water containing sodium and cause pseudo-hyponatremia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/38\" class=\"abstract_t\">38</a>]. Serum triglyceride levels &gt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> may cause a falsely normal amylase level, likely from interference of the calorimetric reading. Serial dilutions of the serum amylase sample can reduce the triglyceride interference [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/38,39\" class=\"abstract_t\">38,39</a>].</p><p class=\"headingAnchor\" id=\"H274073233\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia-induced pancreatitis should be suspected in patients with acute pancreatitis and risk factors for hypertriglyceridemia. Risk factors for hypertriglyceridemia include poorly controlled diabetes, alcoholism, obesity, pregnancy, prior pancreatitis, and a personal or family history of hypertriglyceridemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1,2,4,14,40\" class=\"abstract_t\">1,2,4,14,40</a>]. Serum triglyceride levels &gt;1000 <span class=\"nowrap\">mg/dL</span> (11.2 <span class=\"nowrap\">mmol/L)</span> are required for hypertriglyceridemia to be considered the underlying etiology of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/6\" class=\"abstract_t\">6</a>]. </p><p>The diagnosis of acute pancreatitis in patients with hypertriglyceridemia is the same as other etiologies of acute pancreatitis and requires the presence of two of the following three criteria: acute onset of persistent, severe, epigastric pain often radiating to the back, elevation in serum lipase or amylase to three times or greater than the upper limit of normal, and characteristic findings of acute pancreatitis on imaging (contrast-enhanced computed tomography, magnetic resonance imaging, or transabdominal ultrasonography). The diagnosis of acute pancreatitis is discussed in detail separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-pancreatitis#H11665423\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of acute pancreatitis&quot;, section on 'Diagnostic evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of patients with hypertriglyceridemia-induced pancreatitis (HTGP) includes treatment of acute pancreatitis and reduction of serum triglyceride levels with the goal of preventing necrotizing pancreatitis and organ failure.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Treatment of acute pancreatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial management of a patient with acute pancreatitis consists of supportive care with fluid resuscitation, pain control, and nutritional support. The management of acute pancreatitis is discussed in detail separately. (See <a href=\"topic.htm?path=management-of-acute-pancreatitis#H2\" class=\"medical medical_review\">&quot;Management of acute pancreatitis&quot;, section on 'Initial management'</a>.)</p><p class=\"headingAnchor\" id=\"H2036618050\"><span class=\"h2\">Initial therapy for hypertriglyceridemia</span></p><p class=\"headingAnchor\" id=\"H1024986038\"><span class=\"h3\">Choice of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main treatment modalities for initial management of hypertriglyceridemia are apheresis and insulin. However, randomized trials comparing their efficacy are lacking. Our approach to initial therapy for hypertriglyceridemia in patients with HTGP is based on the severity of acute pancreatitis and the presence of worrisome clinical features &#160;(<a href=\"image.htm?imageKey=GAST%2F116993\" class=\"graphic graphic_algorithm graphicRef116993 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/32,41-47\" class=\"abstract_t\">32,41-47</a>]. (See <a href=\"#H1385596772\" class=\"local\">'Patients with worrisome features'</a> below.)</p><p class=\"headingAnchor\" id=\"H1385596772\"><span class=\"h4\">Patients with worrisome features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with HTGP and one or more worrisome feature, we suggest initial therapy with therapeutic plasma exchange (TPE) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/48,49\" class=\"abstract_t\">48,49</a>]. </p><p>Worrisome features in patients with HTGP include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of hypocalcemia</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lactic acidosis </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of worsening systemic inflammation (two or more):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Temperature &gt;38.5&deg;C or &lt;35.0&deg;C</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Heart rate of &gt;90 <span class=\"nowrap\">beats/min</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Respiratory rate of &gt;20 <span class=\"nowrap\">breaths/min</span> or PaCO<sub>2</sub> of &lt;32 mm Hg</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>WBC count of &gt;12,000 <span class=\"nowrap\">cells/mL,</span> &lt;4000 <span class=\"nowrap\">cells/mL,</span> or &gt;10 percent immature (band) forms</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of worsening organ dysfunction or multi-organ failure as defined by Modified Marshall scoring system for organ dysfunction (<a href=\"image.htm?imageKey=GAST%2F87718\" class=\"graphic graphic_table graphicRef87718 \">table 1</a>)</p><p/><p>We administer intravenous insulin if apheresis is unavailable or if the patient cannot tolerate apheresis. </p><p class=\"headingAnchor\" id=\"H1454207828\"><span class=\"h4\">Patients without worrisome features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with acute pancreatitis without worrisome features, we administer intravenous insulin. For management of hypertriglyceridemia, insulin is continued until triglyceride levels are &lt;500 <span class=\"nowrap\">mg/dL</span>. (See <a href=\"#H245080233\" class=\"local\">'Monitoring and duration of therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H3307420939\"><span class=\"h3\">Treatment modalities</span></p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h4\">Apheresis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Apheresis is the process of passing blood through a medical device to separate any components, and returning the remaining components to the body. TPE is the modality of choice for apheresis in patients with HTGP. The process of TPE involves the removal of plasma and replacement with a colloid solution (eg, albumin or plasma) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/50\" class=\"abstract_t\">50</a>]. </p><p>We use citrate as an anticoagulant rather than heparin and initiate apheresis as soon as possible [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/51\" class=\"abstract_t\">51</a>]. However, the benefit of early initiation has not been consistently demonstrated [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/51,52\" class=\"abstract_t\">51,52</a>]. In an observational cohort study that included 103 patients with 111 episodes of hypertriglyceridemic pancreatitis, citrate anticoagulation during plasmapheresis as compared with heparin was associated with a significantly lower mortality (1 versus 11 percent). Citrate anticoagulation was an independent predictor of survival [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/52\" class=\"abstract_t\">52</a>]. Studies comparing TPE replacement fluid (albumin versus fresh frozen plasma) in patients with HTGP are lacking. </p><p>We use apheresis only in selected patients with severe HTGP as there are significant concerns surrounding apheresis including its cost, availability, and efficacy [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/53,54\" class=\"abstract_t\">53,54</a>]. The efficacy of TPE in reducing the severity of hypertriglyceridemia-induced acute pancreatitis or other clinical important endpoints such as mortality has not been established. In addition, the evidence to support the use of apheresis in patients with HTGP is from observational studies, randomized trials are lacking [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/47,53-66\" class=\"abstract_t\">47,53-66</a>]. One study comparing outcomes in 20 TPE-treated patients with historic controls found no difference between standard therapy and TPE with regard to mortality or systemic complications [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/58\" class=\"abstract_t\">58</a>]. </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h4\">Insulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We typically initiate an intravenous (IV) infusion of <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">regular insulin</a> at a rate of 0.1 to 0.3 <span class=\"nowrap\">units/kg/hour</span>. In patients with blood glucose levels between 150 and 200 <span class=\"nowrap\">mg/dL,</span> we administer a separate 5 percent dextrose infusion to prevent hypoglycemia due to the insulin infusion. </p><p>Many insulin regimens have been reported to lower triglyceride levels to less than 500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> over 3.5 to 4 days [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/44-46\" class=\"abstract_t\">44-46</a>]. IV insulin may be more effective than subcutaneous insulin in severe cases of HTGP [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Insulin decreases serum triglyceride levels by enhancing lipoprotein lipase activity, an enzyme that accelerates chylomicron and very low density lipoprotein metabolism to glycerol and fatty free acids [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/67,68\" class=\"abstract_t\">67,68</a>]. Insulin also inhibits hormone-sensitive lipase in adipocytes, which is the key enzyme for breaking down adipocyte triglyceride and releasing FFA into the circulation. Because HTGP often presents in patients with uncontrolled diabetes, insulin can decrease both triglyceride and glucose levels.</p><p class=\"headingAnchor\" id=\"H245080233\"><span class=\"h3\">Monitoring and duration of therapy</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients treated with apheresis, triglycerides should be measured after each cycle of apheresis. We continue apheresis until triglyceride levels are below &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span>. One series of seven patients with an average triglyceride level of 1407 <span class=\"nowrap\">mg/dL</span> (15.8 <span class=\"nowrap\">mmol/L)</span> reported a decrease in mean triglyceride levels to 683 <span class=\"nowrap\">mg/dL</span> (51 percent) after one plasma exchange session [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/60\" class=\"abstract_t\">60</a>]. In another case report, triglycerides were lowered from 2410 (27.2 <span class=\"nowrap\">mmol/L)</span> to 138 <span class=\"nowrap\">mg/dL</span> (1.5 <span class=\"nowrap\">mmol/L)</span> after three days of apheresis alone [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/65\" class=\"abstract_t\">65</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients treated with intravenous insulin, triglyceride levels should be monitored every 12 hours. Serum glucose should be measured every hour and the <span class=\"nowrap\">insulin/5</span> percent dextrose infusion should be adjusted accordingly. Intravenous insulin should be stopped when triglyceride levels are &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L),</span> which typically occurs within a few days. (See <a href=\"#H10\" class=\"local\">'Insulin'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H3336861013\"><span class=\"h2\">Long-term management of hypertriglyceridemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute pancreatitis in patients with hypertriglyceridemia can be prevented by lowering the serum triglyceride level to 200 <span class=\"nowrap\">mg/dL</span> (&lt;2.2 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/69\" class=\"abstract_t\">69</a>]. </p><p>In patients with acute pancreatitis, maintenance of triglyceride levels below 500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> may expedite clinical improvement [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/2\" class=\"abstract_t\">2</a>]. Once triglyceride levels are &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> patients with HTGP, require long term therapy to prevent recurrent acute pancreatitis and to prevent other complications of HTG [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/9\" class=\"abstract_t\">9</a>]. This consists of both pharmacologic therapy and dietary fat restriction. Other nonpharmacologic interventions include weight loss in obese patients, aerobic exercise, avoidance of concentrated sugars and medications that raise serum triglyceride levels, and strict glycemic control in diabetics. The management of hypertriglyceridemia is discussed in detail separately. (See <a href=\"topic.htm?path=hypertriglyceridemia#H723637349\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;, section on 'Management'</a> and <a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">&quot;Lipid lowering with diet or dietary supplements&quot;</a> and <a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors#H2282300936\" class=\"medical medical_review\">&quot;Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors&quot;, section on 'Fibrates'</a> and <a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">&quot;Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease&quot;</a>.)</p><p>Periodic apheresis has been used with some success as continuing therapy after patients have recovered from their initial episode of acute pancreatitis and particularly in patients who are noncompliant with diet and oral drug therapy [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/70\" class=\"abstract_t\">70</a>]. However, there are insufficient data to routinely recommend such an approach.</p><p class=\"headingAnchor\" id=\"H103075661\"><span class=\"h1\">THERAPIES WITH UNCERTAIN BENEFIT</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Heparin</strong> &ndash; The role of heparin is patients with hypertriglyceridemia-induced pancreatitis is controversial. Heparin has been used alone and with insulin to lower triglycerides [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/32,41-43,51,71-73\" class=\"abstract_t\">32,41-43,51,71-73</a>]. We do not use heparin due to the transient nature of reduction of triglyceride levels, potential lipotoxicity from free fatty acids (FFA), and an increased risk of bleeding. Heparin stimulates the release of endothelial lipoprotein lipase into the circulation [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/74\" class=\"abstract_t\">74</a>]. However, the toxic agent in hypertriglyceridemia-induced pancreatitis (HTGP) is FFA, and lowering triglycerides by stimulating their conversion to FFAs is likely to worsen lipotoxicity [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/28\" class=\"abstract_t\">28</a>]. Heparin causes an initial rise in circulating lipoprotein lipase levels that is quickly followed by increased hepatic degradation of lipoprotein lipase [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/75\" class=\"abstract_t\">75</a>]. This degradation contributes to further depletion of plasma stores of lipoprotein lipase and results in an increase in the level of chylomicrons [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/76\" class=\"abstract_t\">76</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hemofiltration</strong> &ndash; In a randomized trial, 66 patients with HTGP presenting within three days after the onset of symptoms were assigned to early high-volume hemofiltration or low molecular-weight heparin combined with insulin [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/77\" class=\"abstract_t\">77</a>]. Early high-volume hemofiltration resulted in reduced triglyceride levels to &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> faster as compared with insulin therapy. However, there were no differences in clinical outcomes, including local pancreatic complications, or the requirement of surgical intervention.</p><p/><p class=\"headingAnchor\" id=\"H1560824484\"><span class=\"h1\">POST-DIAGNOSTIC EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with hypertriglyceridemia-induced pancreatitis should be evaluated for secondary causes of hypertriglyceridemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/51,71,78-81\" class=\"abstract_t\">51,71,78-81</a>]. For patients with hypertriglyceridemia not clearly associated with a secondary cause, family members should be screened with a fasting triglyceride level. (See <a href=\"topic.htm?path=hypertriglyceridemia#H1231026640\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;, section on 'Screening'</a> and <a href=\"topic.htm?path=hypertriglyceridemia#H8\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;, section on 'Causes'</a> and <a href=\"#H4\" class=\"local\">'Secondary hypertriglyceridemia'</a> above.) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/51,71,78-81\" class=\"abstract_t\">51,71,78-81</a>].</p><p class=\"headingAnchor\" id=\"H518210470\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-pancreatitis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute pancreatitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertriglyceridemia (HTG) is one of the most common cause of acute pancreatitis. It is reported to cause 1 to 14 percent of all cases of acute pancreatitis and up to 56 percent of cases during pregnancy. The risk of developing acute pancreatitis is approximately 5 percent with triglycerides &gt;1000 <span class=\"nowrap\">mg/dL</span> (11.2 <span class=\"nowrap\">mmol/L)</span> and 10 to 20 percent with triglycerides &gt;2000 <span class=\"nowrap\">mg/dL</span> (22.6 <span class=\"nowrap\">mmol/L)</span>. (See <a href=\"#H2247604236\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H3440399298\" class=\"local\">'Terminology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary (genetic) and secondary disorders of lipoprotein metabolism are associated with hypertriglyceridemia-induced pancreatitis (HTGP). Triglycerides themselves do not appear to be toxic. Rather, it is the breakdown of triglycerides into toxic free fatty acids by pancreatic lipases that are the cause of lipotoxicity during acute pancreatitis. (See <a href=\"#H3785591660\" class=\"local\">'Etiology'</a> above and <a href=\"#H1937641612\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial clinical presentation of HTGP is similar to that of acute pancreatitis due to other causes; abdominal pain, nausea, and vomiting are the major complaints. Physical examination findings suggestive of underlying hypertriglyceridemia include eruptive xanthomas over the extensor surfaces of the arms, legs, buttocks, and back, hepatosplenomegaly from fatty infiltration and lipemia retinalis. (See <a href=\"#H5\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HTGP should be suspected in patients with acute pancreatitis and risk factors for hypertriglyceridemia. Risk factors for hypertriglyceridemia include poorly controlled diabetes, alcoholism, obesity, pregnancy, prior pancreatitis, and a personal or family history of hypertriglyceridemia. Serum triglyceride levels &gt;1000 <span class=\"nowrap\">mg/dL</span> (11.2 <span class=\"nowrap\">mmol/L)</span> are required for hypertriglyceridemia to be considered the underlying etiology of acute pancreatitis. (See <a href=\"#H274073233\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial management of patients with HTGP includes treatment of acute pancreatitis and reduction of serum triglyceride levels to &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> (<a href=\"image.htm?imageKey=GAST%2F116993\" class=\"graphic graphic_algorithm graphicRef116993 \">algorithm 1</a>). (See <a href=\"#H7\" class=\"local\">'Management'</a> above and <a href=\"topic.htm?path=management-of-acute-pancreatitis\" class=\"medical medical_review\">&quot;Management of acute pancreatitis&quot;</a>.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with HTGP (serum triglyceride level <span class=\"nowrap\">&gt;1000mg/dL</span> plus lipase &gt;3 times the upper limit of normal) <strong>and</strong> signs of hypocalcemia, lactic acidosis, signs of worsening systemic inflammation or organ dysfunction, or multi-organ failure, we suggest treatment with apheresis, and specifically therapeutic plasma exchange (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Triglyceride levels should be monitored every cycle of apheresis. We continue apheresis until triglyceride levels are below &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span>. (See <a href=\"#H9\" class=\"local\">'Apheresis'</a> above and <a href=\"#H245080233\" class=\"local\">'Monitoring and duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients without worrisome features, we suggest initiating therapy with intravenous (IV) <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">regular insulin</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We administer insulin at a rate of 0.1 to 0.3 <span class=\"nowrap\">units/kg/hour</span>. In patients with blood sugar levels between 150 and 200 <span class=\"nowrap\">mg/dL,</span> we administer IV glucose supplementation with a separate 5 percent dextrose infusion to prevent hypoglycemia. Triglyceride levels should be monitored every 12 hours. Serum glucose should be measured every hour and the <span class=\"nowrap\">insulin/5</span> percent dextrose infusion should be adjusted accordingly. Intravenous insulin should be stopped when triglyceride levels are &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span>. (See <a href=\"#H10\" class=\"local\">'Insulin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once triglyceride levels are &lt;500 <span class=\"nowrap\">mg/dL</span> (5.6 <span class=\"nowrap\">mmol/L)</span> patients with HTGP, require long-term therapy to prevent recurrent pancreatitis and to prevent other complications of HTG. This consists of both pharmacologic therapy (eg, oral <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> 600 mg twice daily) and dietary modification (eg, fat- and simple sugar-restricted diet). Other nonpharmacologic interventions include weight loss in obese patients, aerobic exercise, avoidance of concentrated sugars and medications that raise serum triglyceride levels, and strict glycemic control in diabetics. (See <a href=\"#H245080233\" class=\"local\">'Monitoring and duration of therapy'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with HTGP should be evaluated for secondary causes of hypertriglyceridemia. For patients with hypertriglyceridemia not clearly associated with a secondary cause, family members should be screened with a fasting triglyceride level. (See <a href=\"#H1560824484\" class=\"local\">'Post-diagnostic evaluation'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/1\" class=\"nounderline abstract_t\">Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/2\" class=\"nounderline abstract_t\">Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990; 19:783.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/3\" class=\"nounderline abstract_t\">Zhu Y, Pan X, Zeng H, et al. A Study on the Etiology, Severity, and Mortality of 3260 Patients With Acute Pancreatitis According to the Revised Atlanta Classification in Jiangxi, China Over an 8-Year Period. Pancreas 2017; 46:504.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/4\" class=\"nounderline abstract_t\">Chang CC, Hsieh YY, Tsai HD, et al. Acute pancreatitis in pregnancy. Zhonghua Yi Xue Za Zhi (Taipei) 1998; 61:85.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/5\" class=\"nounderline abstract_t\">Koutroumpakis E, Slivka A, Furlan A, et al. Management and outcomes of acute pancreatitis patients over the last decade: A US tertiary-center experience. Pancreatology 2017; 17:32.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/6\" class=\"nounderline abstract_t\">Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2969.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/7\" class=\"nounderline abstract_t\">Wan J, He W, Zhu Y, et al. Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study. Lipids Health Dis 2017; 16:124.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/8\" class=\"nounderline abstract_t\">Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol 2015; 110:1497.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/9\" class=\"nounderline abstract_t\">Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308:804.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/10\" class=\"nounderline abstract_t\">Lindkvist B, Appelros S, Regn&eacute;r S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology 2012; 12:317.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/11\" class=\"nounderline abstract_t\">Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10:157.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/12\" class=\"nounderline abstract_t\">Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med 2013; 173:162.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/13\" class=\"nounderline abstract_t\">Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37:13.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/14\" class=\"nounderline abstract_t\">Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol 2014; 48:195.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/15\" class=\"nounderline abstract_t\">Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971; 75:471.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/16\" class=\"nounderline abstract_t\">Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012; 272:185.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/17\" class=\"nounderline abstract_t\">Hegele RA, Ban MR, Hsueh N, et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009; 18:4189.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/18\" class=\"nounderline abstract_t\">Havel RJ. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 1982; 66:441.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/19\" class=\"nounderline abstract_t\">Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004; 89:2153.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/20\" class=\"nounderline abstract_t\">Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol 2000; 95:2795.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/21\" class=\"nounderline abstract_t\">Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332:11.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/22\" class=\"nounderline abstract_t\">Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig 2006; 26:297.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/23\" class=\"nounderline abstract_t\">Eskandar O, Eckford S, Roberts TL. Severe, gestational, non-familial, non-genetic hypertriglyceridemia. J Obstet Gynaecol Res 2007; 33:186.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/24\" class=\"nounderline abstract_t\">Whitfield JB, Hensley WJ, Bryden D, Gallagher H. Some laboratory correlates of drinking habits. Ann Clin Biochem 1978; 15:297.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/25\" class=\"nounderline abstract_t\">Haber PS, Wilson JS, Apte MV, et al. Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology 1994; 106:742.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/26\" class=\"nounderline abstract_t\">O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/27\" class=\"nounderline abstract_t\">Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: A case-based review. World J Gastroenterol 2006; 12:7197.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/28\" class=\"nounderline abstract_t\">Navina S, Acharya C, DeLany JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med 2011; 3:107ra110.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/29\" class=\"nounderline abstract_t\">Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf) 2009; 195:13.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/30\" class=\"nounderline abstract_t\">Dominguez-Mu&ntilde;oz JE, Malfertheiner P, Ditschuneit HH, et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol 1991; 10:261.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/31\" class=\"nounderline abstract_t\">Deng LH, Xue P, Xia Q, et al. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol 2008; 14:4558.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/32\" class=\"nounderline abstract_t\">Alag&ouml;zl&uuml; H, Cindoruk M, Karakan T, Unal S. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci 2006; 51:931.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/33\" class=\"nounderline abstract_t\">Durrington P. Dyslipidaemia. Lancet 2003; 362:717.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/34\" class=\"nounderline abstract_t\">Nayak KR, Daly RG. Images in clinical medicine. Eruptive xanthomas associated with hypertriglyceridemia and new-onset diabetes mellitus. N Engl J Med 2004; 350:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/35\" class=\"nounderline abstract_t\">Kumar J, Wierzbicki AS. Images in clinical medicine. Lipemia retinalis. N Engl J Med 2005; 353:823.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/36\" class=\"nounderline abstract_t\">Vipperla K, Somerville C, Furlan A, et al. Clinical Profile and Natural Course in a Large Cohort of Patients With Hypertriglyceridemia and Pancreatitis. J Clin Gastroenterol 2017; 51:77.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/37\" class=\"nounderline abstract_t\">Balachandra S, Virlos IT, King NK, et al. Hyperlipidaemia and outcome in acute pancreatitis. Int J Clin Pract 2006; 60:156.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/38\" class=\"nounderline abstract_t\">Howard JM, Reed J. Pseudohyponatremia in acute hyperlipemic pancreatitis. A potential pitfall in therapy. Arch Surg 1985; 120:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/39\" class=\"nounderline abstract_t\">Fallat RW, Vester JW, Glueck CJ. Suppression of amylase activity by hypertriglyceridemia. JAMA 1973; 225:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/40\" class=\"nounderline abstract_t\">Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003; 36:54.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/41\" class=\"nounderline abstract_t\">Jain D, Zimmerschied J. Heparin and insulin for hypertriglyceridemia-induced pancreatitis: case report. ScientificWorldJournal 2009; 9:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/42\" class=\"nounderline abstract_t\">Henzen C, R&ouml;ck M, Schnieper C, Heer K. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis]. Schweiz Med Wochenschr 1999; 129:1242.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/43\" class=\"nounderline abstract_t\">Berger Z, Quera R, Poniachik J, et al. [heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia. Experience of 5 cases]. Rev Med Chil 2001; 129:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/44\" class=\"nounderline abstract_t\">Jabbar MA, Zuhri-Yafi MI, Larrea J. Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 1998; 17:458.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/45\" class=\"nounderline abstract_t\">Mikhail N, Trivedi K, Page C, et al. Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med 2005; 23:415.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/46\" class=\"nounderline abstract_t\">Tamez-P&eacute;rez HE, S&aacute;enz-Gallegos R, Hern&aacute;ndez-Rodr&iacute;guez K, et al. [Insulin therapy in patients with severe hypertriglyceridemia]. Rev Med Inst Mex Seguro Soc 2006; 44:235.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/47\" class=\"nounderline abstract_t\">Betteridge DJ, Bakowski M, Taylor KG, et al. Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. Lancet 1978; 1:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/48\" class=\"nounderline abstract_t\">Kahn T, Bosch J, Levitt MF, Goldstein MH. Effect of sodium nitrate loading on electrolyte transport by the renal tubule. Am J Physiol 1975; 229:746.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/49\" class=\"nounderline abstract_t\">Yoshino M, Tsukada T, Tsushima K. Inosine nucleosidase from Azotobacter vinelandii. Purification and properties. Arch Microbiol 1978; 119:59.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/50\" class=\"nounderline abstract_t\">Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/51\" class=\"nounderline abstract_t\">Sleth JC, Lafforgue E, Servais R, et al. [A case of hypertriglycideremia-induced pancreatitis in pregnancy: value of heparin]. Ann Fr Anesth Reanim 2004; 23:835.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/52\" class=\"nounderline abstract_t\">Gubensek J, Buturovic-Ponikvar J, Romozi K, Ponikvar R. Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study. PLoS One 2014; 9:e102748.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/53\" class=\"nounderline abstract_t\">Furuya T, Komatsu M, Takahashi K, et al. Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases. Ther Apher 2002; 6:454.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/54\" class=\"nounderline abstract_t\">Stefanutti C, Di Giacomo S, Labbadia G. Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfus Apher Sci 2011; 45:3.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/55\" class=\"nounderline abstract_t\">Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73:259.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/56\" class=\"nounderline abstract_t\">Bae JH, Baek SH, Choi HS, et al. Acute pancreatitis due to hypertriglyceridemia: report of 2 cases. Korean J Gastroenterol 2005; 46:475.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/57\" class=\"nounderline abstract_t\">Bolan C, Oral EA, Gorden P, et al. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 2002; 87:380.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/58\" class=\"nounderline abstract_t\">Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10:2272.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/59\" class=\"nounderline abstract_t\">Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci 2004; 328:290.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/60\" class=\"nounderline abstract_t\">Kadikoylu G, Yavasoglu I, Bolaman Z. Plasma exchange in severe hypertriglyceridemia a clinical study. Transfus Apher Sci 2006; 34:253.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/61\" class=\"nounderline abstract_t\">Kyriakidis AV, Karydakis P, Neofytou N, et al. Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: report of 5 cases. Pancreatology 2005; 5:201.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/62\" class=\"nounderline abstract_t\">Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3:227.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/63\" class=\"nounderline abstract_t\">Mao EQ, Tang YQ, Zhang SD. Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis. World J Gastroenterol 2003; 9:2622.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/64\" class=\"nounderline abstract_t\">Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher 2003; 18:181.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/65\" class=\"nounderline abstract_t\">Kohli RS, Bleibel W, Shetty A, Dhanjal U. Plasmapheresis in the treatment of hypertriglyceridemic pancreatitis with ARDS. Dig Dis Sci 2006; 51:2287.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/66\" class=\"nounderline abstract_t\">Click B, Ketchum AM, Turner R, et al. The role of apheresis in hypertriglyceridemia-induced acute pancreatitis: A systematic review. Pancreatology 2015; 15:313.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/67\" class=\"nounderline abstract_t\">Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/68\" class=\"nounderline abstract_t\">Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37:693.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/69\" class=\"nounderline abstract_t\">Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009; 104:984.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/70\" class=\"nounderline abstract_t\">Piolot A, Nadler F, Cavallero E, et al. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 1996; 13:96.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/71\" class=\"nounderline abstract_t\">Loo CC, Tan JY. Decreasing the plasma triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy: a case report. Am J Obstet Gynecol 2002; 187:241.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/72\" class=\"nounderline abstract_t\">Sharma P, Lim S, James D, et al. Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia. BMJ 1996; 313:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/73\" class=\"nounderline abstract_t\">Jain P, Rai RR, Udawat H, et al. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol 2007; 13:2642.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/74\" class=\"nounderline abstract_t\">KORN ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 1955; 215:1.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/75\" class=\"nounderline abstract_t\">N&auml;sstr&ouml;m B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 2001; 138:206.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/76\" class=\"nounderline abstract_t\">Weintraub M, Rassin T, Eisenberg S, et al. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994; 35:229.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/77\" class=\"nounderline abstract_t\">He WH, Yu M, Zhu Y, et al. Emergent Triglyceride-lowering Therapy With Early High-volume Hemofiltration Against Low-Molecular-Weight Heparin Combined With Insulin in Hypertriglyceridemic Pancreatitis: A Prospective Randomized Controlled Trial. J Clin Gastroenterol 2016; 50:772.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/78\" class=\"nounderline abstract_t\">Achard JM, Westeel PF, Moriniere P, et al. Pancreatitis related to severe acute hypertriglyceridemia during pregnancy: treatment with lipoprotein apheresis. Intensive Care Med 1991; 17:236.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/79\" class=\"nounderline abstract_t\">Yamauchi H, Sunamura M, Takeda K, et al. Hyperlipidemia and pregnancy associated pancreatitis with reference to plasma exchange as a therapeutic intervention. Tohoku J Exp Med 1986; 148:197.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/80\" class=\"nounderline abstract_t\">G&uuml;rsoy A, Kulaksizoglu M, Sahin M, et al. Severe hypertriglyceridemia-induced pancreatitis during pregnancy. J Natl Med Assoc 2006; 98:655.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/abstract/81\" class=\"nounderline abstract_t\">Lykkesfeldt G, Bock JE, Pedersen FD, et al. Excessive hypertriglyceridemia and pancreatitis in pregnancy. Association with deficiency of lipoprotein lipase. Acta Obstet Gynecol Scand 1981; 60:79.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5655 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3440399298\" id=\"outline-link-H3440399298\">TERMINOLOGY</a></li><li><a href=\"#H2247604236\" id=\"outline-link-H2247604236\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3186240998\" id=\"outline-link-H3186240998\">Prevalence</a></li><li><a href=\"#H806594555\" id=\"outline-link-H806594555\">Risk of acute pancreatitis</a></li></ul></li><li><a href=\"#H3785591660\" id=\"outline-link-H3785591660\">ETIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Primary hypertriglyceridemia</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Secondary hypertriglyceridemia</a></li></ul></li><li><a href=\"#H1937641612\" id=\"outline-link-H1937641612\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL FEATURES</a><ul><li><a href=\"#H2925826169\" id=\"outline-link-H2925826169\">Clinical manifestations</a></li><li><a href=\"#H3539763974\" id=\"outline-link-H3539763974\">Laboratory findings</a></li></ul></li><li><a href=\"#H274073233\" id=\"outline-link-H274073233\">DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">MANAGEMENT</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Treatment of acute pancreatitis</a></li><li><a href=\"#H2036618050\" id=\"outline-link-H2036618050\">Initial therapy for hypertriglyceridemia</a><ul><li><a href=\"#H1024986038\" id=\"outline-link-H1024986038\">- Choice of therapy</a><ul><li><a href=\"#H1385596772\" id=\"outline-link-H1385596772\">Patients with worrisome features</a></li><li><a href=\"#H1454207828\" id=\"outline-link-H1454207828\">Patients without worrisome features</a></li></ul></li><li><a href=\"#H3307420939\" id=\"outline-link-H3307420939\">- Treatment modalities</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Apheresis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Insulin</a></li></ul></li><li><a href=\"#H245080233\" id=\"outline-link-H245080233\">- Monitoring and duration of therapy</a></li></ul></li><li><a href=\"#H3336861013\" id=\"outline-link-H3336861013\">Long-term management of hypertriglyceridemia</a></li></ul></li><li><a href=\"#H103075661\" id=\"outline-link-H103075661\">THERAPIES WITH UNCERTAIN BENEFIT</a></li><li><a href=\"#H1560824484\" id=\"outline-link-H1560824484\">POST-DIAGNOSTIC EVALUATION</a></li><li><a href=\"#H518210470\" id=\"outline-link-H518210470\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/5655|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=GAST/116993\" class=\"graphic graphic_algorithm\">- Management HTGP</a></li></ul></li><li><div id=\"GAST/5655|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/58261\" class=\"graphic graphic_picture\">- TG lactescent serum sample</a></li></ul></li><li><div id=\"GAST/5655|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/87718\" class=\"graphic graphic_table\">- Modified Marshall scoring system for organ dysfunction</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-pancreatitis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-of-acute-pancreatitis\" class=\"medical medical_review\">Etiology of acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-hypercholesterolemia-in-adults-overview\" class=\"medical medical_review\">Familial hypercholesterolemia in adults: Overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">Hypertriglyceridemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia\" class=\"medical medical_review\">Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">Lipid lowering with diet or dietary supplements</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors\" class=\"medical medical_review\">Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-pancreatitis\" class=\"medical medical_review\">Management of acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-pancreatitis\" class=\"medical medical_society_guidelines\">Society guideline links: Acute pancreatitis</a></li></ul></div></div>","javascript":null}